Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Immunity to cancer stem cells may help protect people with a precancerous condition from developing the full-blown disease

Although stem cells hold incredible promise in the fight against certain diseases, in cancer they're anything but helpful. In fact, mounting evidence is showing that a tumor's growth and spread may depend on "cancer stem cells," which comprise only a very small subset of the tumor.

2 Apr 2007

Immune response to cancer stem cells may dictate cancer's course

Although stem cells hold incredible promise in the fight against certain diseases, in cancer they're anything but helpful. In fact, mounting evidence is showing that a tumor's growth and spread may depend on 'cancer stem cells,' which comprise only a very small subset of the tumor.

27 Mar 2007

Two novel therapies for multiple myeloma

Two novel biologics are currently being investigated for their potential benefit to multiple myeloma patients in separate ongoing clinical trials at NewYork-Presbyterian Hospital/Weill Cornell Medical Center.

14 Mar 2007

Mayo Clinic tests engineered measles virus against multiple myeloma

Mayo Clinic Cancer Center has opened a new Phase I clinical trial testing an engineered measles virus against multiple myeloma, a cancer of the bone marrow that currently has no cure. This is the third of a series of molecular medicine studies in patients testing the potential of measles to kill cancer.

5 Mar 2007

Researchers wake up viruses inside tumors to image and then destroy cancers

They say this strategy could offer a novel way of treating many cancers associated with Epstein-Barr, including at least four different types of lymphoma and nasopharyngeal and gastric cancers.

1 Mar 2007

Chemotherapy drug bortezomib packs a one-two punch

Cancer can be wily, and those who treat the disease have amassed a wide array of weapons with which to fight it and kill tumors.

20 Feb 2007

Rate of stem cell transplants among African-Americans lower

Lower transplant rates in ethnic communities may be explained somewhat by a lack of suitable anonymous donors, a problem the medical community has long known and been working to address. Surprisingly, the study found the discrepancy in treatment held true even when the transplant was autologous (e.g. self-donated stem cells were used) or when the cells were donated by a relative, typically a sibling.

11 Feb 2007

Turning the immune system against cancer

Medicine can now prevent a host of diseases with a mere shot of vaccine. Polio and smallpox are almost non-existent, and mumps and chicken pox are rarely seen nowadays.

4 Aug 2006

Roswell Park research aids development of myeloma drug

Roswell Park Cancer Institute (RPCI) researchers played a leading role in clinical studies which led to U.S. Food and Drug Administration (FDA) approval of a new treatment for patients diagnosed with multiple myeloma - the second most common blood cancer.

11 Jul 2006

Scientists identify overactive protein that plays a key role in cystic fibrosis

A team led by Johns Hopkins Children's Center scientists has identified and successfully tamed an overactive protein that plays a key role in cystic fibrosis (CF), a genetic disorder that interferes with the body's ability to transport chloride in and out of cells.

5 Jul 2006

Bortezomib extends lung cancer survival

Adding the new molecularly targeted agent bortezomib to a standard chemotherapy regimen of gemcitabine and carboplatin prolongs survival in patients with advanced non-small cell lung cancer, according to results from a phase II trial.

9 Jun 2006

Thalomid gets FDA approval to treat multiple myeloma

Thalomid (thalidomide) has been given a new lease of life following the United States Food and Drug Administration (FDA) approval for the drug to be used in combination with the steroid dexamethasone for the treatment of newly diagnosed multiple myeloma.

29 May 2006

A review of percutaneous kyphoplasty

A procedure that fills in fractured vertebrae with injected cement has not been shown to improve a person's back pain or quality of life, according to a new analysis of studies.

16 May 2006

Four subtypes of blood cancer identified

Scientists at Dana-Farber Cancer Institute and collaborators have identified four distinct genetic subtypes of multiple myeloma, a deadly blood cancer, that have different prognoses and might be treated most effectively with drugs specifically targeted to those subtypes.

26 Apr 2006

Breast implants not associated with an increased risk of cancer

Implants were associated with a decrease in breast cancer risk and an increased lung cancer risk, but these results likely reflect the lifestyles and smoking habits of the women in the study rather than an effect of the implants themselves, the authors conclude.

18 Apr 2006

Thalidomide improves remission in myeloma

Myeloma is one of the least curable cancers and involves plasma cells, the white blood cells that produce antibodies.

9 Mar 2006

FDA grants priority review for Revlimid

Celgene Corporation announced that the U.S. Food and Drug Administration (FDA) has granted a Priority Review designation to its Supplemental New Drug Application (sNDA) for REVLIMID (lenalidomide) for the treatment of relapsed or refractory multiple myeloma.

6 Mar 2006

Loyola to study for first time IV medication for osteopenia and inflammatory bowel diseases

Researchers at the Osteoporosis and Metabolic Bone Disease Center and the Division of Gastroenterology at Loyola University Health System are studying a once-yearly, 15-minute infusion of an intravenous (IV) medication in patients with osteopenia (low bone mass) and inflammatory bowel diseases (IBD) that, if proven effective, may be considered the standard of treatment.

10 Jan 2006

Thalomid gives hope for blood cancer sufferers

Drug company Celgene says it has halted a pivotal-stage trial of its Thalomid drug earlier than expected after the drug was shown to dramatically limit the progress of the blood cancer multiple myeloma.

9 Jan 2006

Compound from Salinispora (marine bacteria) kills blood cancer cells

An anti-cancer compound derived from bacteria dwelling in ocean-bottom sediments appears in laboratory tests to be a potent killer of drug-resistant multiple myeloma cells, and potentially with less toxicity than current treatments, report Dana-Farber Cancer Institute researchers in the November issue of Cancer Cell.

21 Nov 2005